Pipelines
Novel E3 Ligands Represent the Future of Targeted Protein Degraders
At Cullgen, we believe the future of targeted protein degraders lies in the discovery and utilization of novel E3 ligands. We have identified and found numerous E3 ligands to several previously unexplored E3 ligases that are either functionally essential, tissue specific, or tissue restrictive. Access to such E3 ligases provides Cullgen with additional tools to selectively degrade disease-causing proteins.
Our pipeline of novel E3 ligands is shown below. For more detail regarding our work on novel E3 ligands, click here.
Cullgen’s Novel E3 Ligand Discovery Pipeline
Broad Pipeline of Targeted Protein Degraders
Cullgen’s pipeline of targeted protein degraders is focused primarily on oncology. Our most advanced degrader program is a pan-TRK degrader that is currently under evaluation in a phase I clinical trial for solid tumors. Three of our newer degraders feature the use of novel E3 ligands, and two of our programs have been partnered with Astellas.
Cullgen’s Degrader Pipeline: Chronological Advancement
